Dies ist eine HTML Version eines Anhanges der Informationsfreiheitsanfrage 'DG GROW contacts re. pharma incentives study'.



Ref. Ares(2018)1499108 - 19/03/2018
Ref. Ares(2019)631504 - 04/02/2019
From: 
 (CAB-BIENKOWSKA) 
Sent: 
Monday 19 March 2018 14:09 
To: 
CAB BIENKOWSKA ARCHIVES 
Subject: 
FW: IP Incentives analysis & SPCs - Meeting request with EFPIA 
 
 
 
From: Nathalie Moll [mailto:[Emailadresse]]  
Sent: Monday, March 19, 2018 2:00 PM 
To: 
 (CAB-BIENKOWSKA) 
Cc: 
 (CAB-BIENKOWSKA); 
 
Subject: IP Incentives analysis & SPCs - Meeting request with EFPIA 
 
Dear Mr Husak, 
 
I am contacting you in my capacity of Director General of the European 
Federation of Pharmaceutical Industries and Associations (EFPIA) regarding the 
currently ongoing analysis of intellectual property incentives related to the 
pharmaceutical sector. EFPIA represents 1,900 pharmaceutical innovative 
companies committed to researching, developing and bringing new therapies to 
patients that will improve their health and quality of life while positively 
contributing to the EU economy. 
 
The ongoing analysis and most notably the discussions on amending the 
framework for Supplementary Protection Certificates (SPCs), are of utmost 
importance to our industry. Intellectual Property including SPCs are imperative for 
fostering and safeguarding the significant investments in research and 
development of new and innovative medicines. 
 
I would like to follow up on the initial discussion a delegation of our Board held 
with Commissioner Bieńkowska on 30th January 2018 with regard to the recent 
swift developments in relation to the SPC. Having followed the process closely, 
the innovative industry has reacted to the various positions and arguments that 
have been brought forward and we have developed our views further as EFPIA. 
We have identified a possible option that could be supported by all stakeholders 
involved and hope that this could allow for it to be considered in the final stages of 
decision making.  
 
I would be most appreciative if we could discuss this matter further during a 
personal meeting at your earliest convenience and will of course adapt to your 
availabilities.  
 
Thank you in advance for your time and kind consideration. 
 
Yours sincerely, 
 
Nathalie Moll 



 
Nathalie Moll 
Director General 
EFPIA - European Federation of Pharmaceutical Industries and Associations 
Leopold Plaza Building 
Rue du Trône 108 
B-1050 Bruxelles 
 
Tel: +3226262540 (Direct Line) 
Tel: +3226262555 (Switchboard) 
Email: [Emailadresse] 
www.efpia.eu  
 
 
 
Electronically signed on 04/02/2019 15:18 (UTC+01) in accordance with article 4.2 (Validity of electronic documents) of Commission Decision 2004/563

Document Outline